• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Sage Therapeutics Slumps As Biogen Deal May Dampen M&A Hopes

By Kurt Osterberg · On April 20, 2018

Weakness in shares of Sage Therapeutics (SAGE) may be related to news that Biogen (BIIB) and Ionis Pharmaceuticals (IONS) have expanded their strategic collaboration through a new ten-year collaboration agreement, which may be read by some market participants as lowering the odds for M&A action related to Sage.

Under the terms of the collaboration, Biogen will pay Ionis $1B in cash, which will include $625M to purchase 11,501,153 shares of Ionis common stock at an approximately 25% cash premium, and a $375M upfront payment. On April 24, 2017, Sage announced the appointment of Michael Cloonan as Chief Business Officer. Cloonan had come to Sage from Biogen, where he worked for 14 years. On the date of that announcement, Adam Feuerstein of STAT tweeted, “$SAGE expands exec team, including former $BIIB – er Michael Cloonan as new Chief Business Officer. Stand down on $SAGE takeout for now.” More recently, on April 10, 2018, shares of Sage has spiked higher in afternoon trading amid rumors of the company canceling from a planned presentation. A spokesperson for Sage Therapeutics told The Fly the company “cancelled participation in the JPMorgan meeting due to some travel logistics issues.” In March, Canaccord analyst Sumant Kulkarni had assumed Sage Therapeutics with a Buy rating, citing among other things “a high scarcity value in its robust/ripening CNS platforms.”

In midday trading, Sage shares are down $17.90, or 10.5%, to $151.77.

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

  • Finance

    NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

  • Finance

    5 NFTs Trending on Twitter Going Cheap to Invest in Now

No Comments

Leave a reply Cancel reply

Top Finance

  • 3 Best Large-Cap Blend Mutual Funds For Enticing Returns 3 Best Large-Cap Blend Mutual Funds For Enticing Returns
  • What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage
  • Hedge Funds In The US Hedge Funds In The US
  • 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement
  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce

New Posts

  • STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

    STEPN Sneaker NFTs Sell For $100, Previously Worth $1200

    June 20, 2022
  • NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

    NFT Prices in Free Fall – 5 NFT Collections to Start Buying Today

    June 20, 2022
  • 5 NFTs Trending on Twitter Going Cheap to Invest in Now

    5 NFTs Trending on Twitter Going Cheap to Invest in Now

    June 20, 2022
  • Bill Gates – ‘NFTs & Crypto Based on Greater Fool Theory’

    Bill Gates – ‘NFTs & Crypto Based on Greater Fool Theory’

    June 20, 2022
  • Actor Seth Green Pays $300,000 to Recover his Stolen BAYC NFT

    Actor Seth Green Pays $300,000 to Recover his Stolen BAYC NFT

    June 20, 2022
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.